109 related articles for article (PubMed ID: 34856511)
1. Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs.
Franken MG; Leeneman B; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; Boers-Sonderen MJ; van den Eertwegh AJM; de Groot JWB; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; van der Veldt AAM; Westgeest HM; Wouters MWJM; Haanen JBAG; Uyl-de Groot CA
ESMO Open; 2021 Dec; 6(6):100320. PubMed ID: 34856511
[TBL] [Abstract][Full Text] [Related]
2. Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort.
Kandel M; Allayous C; Dalle S; Mortier L; Dalac S; Dutriaux C; Leccia MT; Guillot B; Saiag P; Lacour JP; Legoupil D; Lesimple T; Aubin F; Beylot-Barry M; Brunet-Possenti F; Arnault JP; Granel-Brocard F; Stoebner PE; Dupuy A; Maubec E; Grob JJ; Dreno B; Rotolo F; Ballon A; Michiels S; Lebbe C; Borget I
Eur J Cancer; 2018 Dec; 105():33-40. PubMed ID: 30384014
[TBL] [Abstract][Full Text] [Related]
3. Changes in Health Care Costs, Survival, and Time Toxicity in the Era of Immunotherapy and Targeted Systemic Therapy for Melanoma.
Bateni SB; Nguyen P; Eskander A; Seung SJ; Mittmann N; Jalink M; Gupta A; Chan KKW; Look Hong NJ; Hanna TP
JAMA Dermatol; 2023 Nov; 159(11):1195-1204. PubMed ID: 37672282
[TBL] [Abstract][Full Text] [Related]
4. Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs.
Leeneman B; Uyl-de Groot CA; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; van den Eertwegh AJM; de Groot JWB; Herbschleb KH; van der Hoeven JJM; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; Wouters MWJM; Haanen JBAG; Franken MG
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32325748
[TBL] [Abstract][Full Text] [Related]
5. Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study).
McArthur GA; Mohr P; Ascierto PA; Arance A; Banos Hernaez A; Kaskel P; Weichenthal M; Shinde R; Stevinson K
Oncologist; 2017 Aug; 22(8):951-962. PubMed ID: 28526721
[TBL] [Abstract][Full Text] [Related]
6. Association of Sociodemographic Factors With Immunotherapy Receipt for Metastatic Melanoma in the US.
Moyers JT; Patel A; Shih W; Nagaraj G
JAMA Netw Open; 2020 Sep; 3(9):e2015656. PubMed ID: 32876684
[TBL] [Abstract][Full Text] [Related]
7. Association of Innovations in Radiotherapy and Systemic Treatments With Clinical Outcomes in Patients With Melanoma Brain Metastasis From 2007 to 2016.
Brastianos HC; Nguyen P; Sahgal A; Eisenhauer EA; Baetz T; Hanna TP
JAMA Netw Open; 2020 Jul; 3(7):e208204. PubMed ID: 32663310
[TBL] [Abstract][Full Text] [Related]
8. Economic Burden of Adverse Events Associated with Immunotherapy and Targeted Therapy for Metastatic Melanoma in the Elderly.
Ghate SR; Li Z; Tang J; Nakasato AR
Am Health Drug Benefits; 2018 Oct; 11(7):334-343. PubMed ID: 30647822
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of the Dabrafenib Schedule in Combination With Trametinib Compared With Other Targeted Therapies, Immunotherapy, and Dacarbazine for the Treatment of Unresectable or Metastatic Melanoma With BRAFV600 Mutation in Colombia.
Gil-Rojas Y; Lasalvia P; Hernández F; Castañeda-Cardona C; Castrillón-Correa J; Herrera D; Rosselli D
Value Health Reg Issues; 2021 Dec; 26():182-190. PubMed ID: 34673349
[TBL] [Abstract][Full Text] [Related]
10. Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands.
Franken MG; Leeneman B; Jochems A; Schouwenburg MG; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; van den Eertwegh AJM; de Groot JWB; van der Hoeven KJM; Hospers GAP; Kapiteijn E; Koornstra R; Kruit WHJ; Louwman MWJ; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; Vreugdenhil G; Wouters MWJM; van Zeijl M; Haanen JBAG; Uyl-de Groot CA
Anticancer Drugs; 2018 Jul; 29(6):579-588. PubMed ID: 29634490
[TBL] [Abstract][Full Text] [Related]
11. Melanoma-related costs by disease stage and phase of management in Ireland.
Crealey GE; Hackett C; Harkin K; Heckmann P; Kelleher F; Lyng Á; McCarthy T; McEnery M; Meaney C; Roche D; Tobin AM
J Public Health (Oxf); 2023 Aug; 45(3):714-722. PubMed ID: 37169550
[TBL] [Abstract][Full Text] [Related]
12. [Recent treatment results for metastatic melanoma: data from the Dutch Melanoma Treatment Registry].
van Zeijl MCT; van den Eertwegh AJM; Wouters MWJM; Jochems A; Schouwenburg MG; Haanen JBAG; Aarts MJ; van den Berkmortel FWPJ; de Groot JWB; Hospers GAP; Kapiteijn E; Koornstra RH; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van der Hoeven KJM
Ned Tijdschr Geneeskd; 2018 Jun; 162():. PubMed ID: 30040270
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of everolimus for second-line treatment of metastatic renal cell carcinoma in Serbia.
Mihajlović J; Pechlivanoglou P; Sabo A; Tomić Z; Postma MJ
Clin Ther; 2013 Dec; 35(12):1909-22. PubMed ID: 24238790
[TBL] [Abstract][Full Text] [Related]
14. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.
Dreno B; Thompson JF; Smithers BM; Santinami M; Jouary T; Gutzmer R; Levchenko E; Rutkowski P; Grob JJ; Korovin S; Drucis K; Grange F; Machet L; Hersey P; Krajsova I; Testori A; Conry R; Guillot B; Kruit WHJ; Demidov L; Thompson JA; Bondarenko I; Jaroszek J; Puig S; Cinat G; Hauschild A; Goeman JJ; van Houwelingen HC; Ulloa-Montoya F; Callegaro A; Dizier B; Spiessens B; Debois M; Brichard VG; Louahed J; Therasse P; Debruyne C; Kirkwood JM
Lancet Oncol; 2018 Jul; 19(7):916-929. PubMed ID: 29908991
[TBL] [Abstract][Full Text] [Related]
15. Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands.
Jochems A; Schouwenburg MG; Leeneman B; Franken MG; van den Eertwegh AJ; Haanen JB; Gelderblom H; Uyl-de Groot CA; Aarts MJ; van den Berkmortel FW; Blokx WA; Cardous-Ubbink MC; Groenewegen G; de Groot JW; Hospers GA; Kapiteijn E; Koornstra RH; Kruit WH; Louwman MW; Piersma D; van Rijn RS; Ten Tije AJ; Vreugdenhil G; Wouters MW; van der Hoeven JJ
Eur J Cancer; 2017 Feb; 72():156-165. PubMed ID: 28030784
[TBL] [Abstract][Full Text] [Related]
16. Survival trends among patients with metastatic melanoma in the pretargeted and the post-targeted era: a US population-based study.
Uprety D; Bista A; Chennamadhavuni A; Niroula A; Jafri SIM; Smith A; Arjyal L
Melanoma Res; 2018 Feb; 28(1):56-60. PubMed ID: 29023264
[TBL] [Abstract][Full Text] [Related]
17. End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma: A Nationwide Cohort Study.
van Breeschoten J; Ismail RK; Wouters MWJM; Hilarius DL; de Wreede LC; Haanen JB; Blank CU; Aarts MJB; van den Berkmortel FWPJ; de Groot JWB; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Stevense-den Boer MA; van der Veldt AAM; Vreugdenhil G; Boers-Sonderen MJ; Suijkerbuijk KPM; van den Eertwegh AJM
JCO Oncol Pract; 2022 Oct; 18(10):e1611-e1620. PubMed ID: 35944229
[TBL] [Abstract][Full Text] [Related]
18. Association of Immunotherapy With Overall Survival in Elderly Patients With Melanoma.
Perier-Muzet M; Gatt E; Péron J; Falandry C; Amini-Adlé M; Thomas L; Dalle S; Boespflug A
JAMA Dermatol; 2018 Jan; 154(1):82-87. PubMed ID: 29214290
[TBL] [Abstract][Full Text] [Related]
19. Survival and cost-effectiveness of hospice care for metastatic melanoma patients.
Huo J; Lairson DR; Du XL; Chan W; Buchholz TA; Guadagnolo BA
Am J Manag Care; 2014 May; 20(5):366-73. PubMed ID: 25181566
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
